



Dr. Anthony Saleh is a biotech entrepreneur and the founder and Chief Executive Officer of miRecule, Inc., a biotechnology company pioneering next-generation RNA therapeutics. Under his leadership, miRecule has developed a proprietary Antibody-RNA Conjugate (ARC) discovery platform, tailored to treat genetic neuromuscular disorders. Dr. Saleh spearheaded the company's strategic collaboration and exclusive licensing agreement with Sanofi to co-develop and commercialize a best-in-class ARC therapy for Facioscapulohumeral Muscular Dystrophy (FSHD)—the second most common form of muscular dystrophy. Prior to miRecule, Dr. Saleh founded multiple biotech startups and held leadership roles at companies including MIMETAS US and Nitron Therapeutics. He also spent a decade as an Investigator at the National Institutes of Health, where he focused on RNA therapeutic development. Dr. Saleh earned his Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University, and his B.S. in Biochemistry from St. Bonaventure University. He is an author and inventor on more than 50 patents, peer-reviewed publications, and book chapters.